(Total Views: 507)
Posted On: 08/11/2020 2:02:00 PM
Post# of 153888
Not a cheerleader..not a basher..long as of this moment the stock...in summary:
1. In many ways trial results nullify Patterson’s paper as double blind is the gold standard although Patterson’s paper would be a cherry on the sundae.
2. The only two milestones left are the severe trial and a BLA for...anything.
I hope the severe study nails it. Many people on this board have rightly pointed this out. I personally don’t believe being a little (?) better than current standard of care will be enough for FDA approval. Not saying it won’t happen but refuse to whistle in the dark.
1. In many ways trial results nullify Patterson’s paper as double blind is the gold standard although Patterson’s paper would be a cherry on the sundae.
2. The only two milestones left are the severe trial and a BLA for...anything.
I hope the severe study nails it. Many people on this board have rightly pointed this out. I personally don’t believe being a little (?) better than current standard of care will be enough for FDA approval. Not saying it won’t happen but refuse to whistle in the dark.
(3)
(0)
